Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae015 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2024. Verfasst von Kaori Takahashi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Ja…. Hauptthemen laut MEDLINE: Breast Neoplasms, Proton Pump Inhibitors, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Keio Gijuku Fukuzawa Memorial Fund, Policy-Based Medical Services Foundation.
Abstract (Originalsprache)
Background
Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment. Patients and Methods This multicenter, retrospective, observational study, conducted across 4 medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio.
Results
The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival period was 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% CI, 0.70-2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61-2.47). Consistent results were obtained for subgroups receiving palbociclib (n = 177) and abemaciclib (n = 63) without propensity score matching. Adverse event incidence and severity were similar in both groups.
Conclusion
The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.
- Department of Industrial Engineering and Economics, Tokyo Institute of Technology, Tokyo, Japan.
- Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
- Department of Pharmacy, Miyagi Cancer Center, Miyagi, Japan.
- Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
ORCID-Profile: Hitoshi Kawazoe
Förderung
- Keio Gijuku Fukuzawa Memorial Fund
- Policy-Based Medical Services Foundation
Zitieren
APA
Takahashi, K., Uozumi, R., Mukohara, T., Hayashida, T., Iwabe, M., Iihara, H., Kusuhara-Mamishin, K., Kitagawa, Y., Tsuchiya, M., Kitahora, M., Nagayama, A., Kosaka, S., Asano-Niwa, Y., Seki, T., Ohnuki, K., Suzuki, A., Ono, F., Futamura, M., Kawazoe, H., & Nakamura, T. (2024). Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyae015
Vancouver
Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, et al. Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer. The Oncologist. 2024. doi:10.1093/oncolo/oyae015
BibTeX
@article{Takahashi2024,
author = {Takahashi, Kaori and Uozumi, Ryuji and Mukohara, Toru and Hayashida, Tetsu and Iwabe, Midori and Iihara, Hirotoshi and Kusuhara-Mamishin, Kanako and Kitagawa, Yuko and Tsuchiya, Masami and Kitahora, Mika and Nagayama, Aiko and Kosaka, Shinkichi and Asano-Niwa, Yoshimi and Seki, Tomoko and Ohnuki, Koji and Suzuki, Akio and Ono, Fumiko and Futamura, Manabu and Kawazoe, Hitoshi and Nakamura, Tomonori},
title = {Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae015}
}
EUVIMED